Christina is the associate editorial director of The American Journal of Managed Care® (AJMC®) and The American Journal of Accountable Care® (AJAC), and joined AJMC in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.
She has a BS in public health from Rutgers University. You can connect with Christina on LinkedIn.
Race, Socioeconomic Status Linked to Rehospitalizations Among Patients With Advanced Cancer
August 30th 2017A new study finds that individuals with advanced cancer have high rates of hospitalization in the year after diagnosis. Palliative care aimed at preventing hospital admissions may be a useful tool, especially for the populations most at risk of rehospitalization.
Texas Hospitals Use Social Networks to Seek Volunteer Nurses for Hurricane Relief Efforts
August 30th 2017Through the power of social media, hospitals in Texas are asking nurses from across the country to lend a hand in assisting the overwhelmed staff who have been working overtime to care for survivors of Hurricane Harvey.
Texas, Coping With Public Health Emergency After Hurricane Harvey, Asks Payers for Flexibility
August 28th 2017The state of Texas remains in a public health emergency after the landfall of Hurricane Harvey as first responders rush to meet emergency medical needs and officials urge insurers to loosen restrictions on care delivery.
CBO Releases Letter Defending Its AHCA Analysis and Integrity
August 25th 2017In response to the questions raised about its objectivity and the methodology of its projections, the Congressional Budget Office (CBO) has released a letter defending the impartiality of its work and explaining how it estimated the impact of House Republicans’ proposed healthcare bill, the American Health Care Act (AHCA).
Liraglutide Gains New Indication for Reducing CV Event Risk
August 25th 2017Novo Nordisk announced that its diabetes drug liraglutide (Victoza) has been approved by the FDA for a new indication: it can reduce the risk of major cardiovascular (CV) events in patients with type 2 diabetes (T2D) and existing CV disease.
5 Strategies From National Immunization Awareness Month to Boost Vaccination Rates
August 25th 2017Several studies and commentaries published during National Immunization Awareness Month have addressed strategies to bring the vaccine coverage rate higher. Here are 5 promising tactics discussed this month for boosting immunization rates.
Report Analyzes Advantages, Drawbacks of Small Businesses' Health Benefits
August 24th 2017A new report finds that small businesses in the US are offering health benefits that are competitive with those offered by larger employers, but that workers at the smallest companies tend to pay higher premium costs.
Predictive Tool Could Target Patients at Risk of Hypoglycemia-Related Utilization
August 24th 2017Researchers have outlined a 6-item risk stratification tool that successfully predicted the likelihood that patients with diabetes will have a hypoglycemia-related emergency department visit or hospital admission.
MACRA Proposal Comment Period Draws Suggestions From Groups, Individual Providers
August 23rd 2017With the comment period now concluded, CMS has received nearly 1300 comments on its proposed amendments to the Quality Payment Program established by the Medicare Access and CHIP Reauthorization Act (MACRA).
Health Center Week Celebrated With HHS Grant As FQHC Staff Report Workplace Woes
August 16th 2017As HHS celebrates National Health Center Week by announcing $105 million in grants for quality improvement, a study indicates that practice transformation may be taking a toll on satisfaction among clinicians and staff at some federally qualified health centers.
Cancer Drug Price Increases Cost Medicaid Millions in Extra Spending, Analysis Shows
August 15th 2017An analysis by Kaiser Health News found that Medicaid incurred billions of dollars in extra spending as a result of price increases for hundreds of common drugs from 2015 to 2016, including decades-old branded drugs and generics used to treat cancer.